CA2425789A1 - Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete. - Google Patents

Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete. Download PDF

Info

Publication number
CA2425789A1
CA2425789A1 CA002425789A CA2425789A CA2425789A1 CA 2425789 A1 CA2425789 A1 CA 2425789A1 CA 002425789 A CA002425789 A CA 002425789A CA 2425789 A CA2425789 A CA 2425789A CA 2425789 A1 CA2425789 A1 CA 2425789A1
Authority
CA
Canada
Prior art keywords
perilipin
agent
isoform
ability
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002425789A
Other languages
English (en)
Inventor
Lawrence Chan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2425789A1 publication Critical patent/CA2425789A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des techniques de criblage permettant d'identifier des composés qui modulent l'activité ou l'expression de la périlipine. L'invention traite également de méthodes et de compositions thérapeutiques visant à prévenir ou à traiter les problèmes de poids ou le diabète, et consistant à administrer aux sujets des composés qui modulent l'activité ou l'expression de la périlipine. Dans un mode de réalisation, l'invention traite de méthodes et compositions qui ont un effet antagoniste sur l'activité ou l'expression de la périlipine afin de traiter et/ou prévenir l'obésité ou le diabète, et de renforcer le métabolisme lipidique de même que la masse musculaire. Dans un autre mode de réalisation, l'invention a trait à des méthodes et compositions qui ont un effet agoniste sur l'activité de la périlipine afin de renforcer l'accumulation des lipides chez un sujet dans le but d'augmenter le gain pondéral.
CA002425789A 2000-10-05 2001-10-05 Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete. Abandoned CA2425789A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23827200P 2000-10-05 2000-10-05
US60/238,272 2000-10-05
PCT/US2001/031400 WO2002028410A1 (fr) 2000-10-05 2001-10-05 Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete.

Publications (1)

Publication Number Publication Date
CA2425789A1 true CA2425789A1 (fr) 2002-04-11

Family

ID=22897193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002425789A Abandoned CA2425789A1 (fr) 2000-10-05 2001-10-05 Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete.

Country Status (5)

Country Link
EP (1) EP1322320A1 (fr)
JP (1) JP2004510965A (fr)
AU (1) AU2002211510A1 (fr)
CA (1) CA2425789A1 (fr)
WO (1) WO2002028410A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029272A1 (en) * 2002-08-06 2004-02-12 Isis Pharmaceuticals Inc. Antisense modulation of perilipin expression
FR2921267B1 (fr) * 2007-09-25 2013-05-17 Clarins Lab Composition cosmetique amincissante
EP3695883A1 (fr) * 2019-02-13 2020-08-19 Alytas Therapeutics GmbH Moyens pour éliminer spécifiquement le fragment de périlipine-1 présentant des adipocytes
KR102177338B1 (ko) * 2019-05-16 2020-11-10 포항공과대학교 산학협력단 N-말단 아세틸화에 의한 페릴리핀2 단백질의 분해 조절 및 이를 이용한 지방 방울 조절방법
US20240287517A1 (en) * 2021-06-16 2024-08-29 Empirico Inc. Treatment of plin1 related diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2162292A (en) * 1991-06-11 1993-01-12 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Perilipin
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein

Also Published As

Publication number Publication date
WO2002028410A9 (fr) 2003-07-24
WO2002028410A1 (fr) 2002-04-11
EP1322320A1 (fr) 2003-07-02
AU2002211510A1 (en) 2002-04-15
JP2004510965A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
US6623947B2 (en) Human glucose-6-phosphatase molecules and uses thereof
EP2110434A1 (fr) Recepteur de cytokine de type 1 GLM-R
JP2006516895A (ja) １７２２、１０２８０、５９９１７、８５５５３、１０６５３、９２３５、２１６６８、１７７９４、２２１０、６１６９、１０１０２、２１０６１、１７６６２、１４６８、１２２８２、６３５０、９０３５、１８２０、２３６５２、７３０１、８９２５、８７０１、３５３３、９４６２、９１２３、１２７８８、１７７２９、６５５５２、１２６１、２１４７６、３３７７０、９３８０、２５６９６５４、３３５５６、５３６５６、４４１４３、３２６１２、１０６７１、２６１、４４５７０、４１９２２、２５５２、２４１７、１９３１９、４３９６９、８９２１、８９９３、９５５、３２３４５、９６６、１９２０、１７３１８、１５１０、１４１８０、２６００５、５５４、１６４０８、４２０２８、１１２０９１、１３８８６、１３９４２、１６７３、５４９４６、または２４１９を使用する、心血管疾患を処置するための方法および組成物
CA2425789A1 (fr) Peripiline utilisee comme cible pour la regulation du poids corporel, de la masse musculaire et du diabete.
US20030082647A1 (en) Transporter protein
JP2008517931A (ja) 脂質関連疾患および障害を処置するための、ＰＧＣ−１βを調節するための方法および組成物
US20020142303A1 (en) Proteins, genes and their use for diagnosis and treatment of Schizophrenia
EP2289908B1 (fr) Utilisation de produits des protéines DG177 sécretées pour la prévention et le traitement de maladies du pancreas et/ou de l'obésité et/ou du syndrome métabolique
AU2002303231B2 (en) NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU2002359580A1 (en) Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
US20030013637A1 (en) Novel anti-autoimmune composition by inhibition of GRF action
JP2005503336A (ja) エネルギー恒常性の調節に関与する、タンパク質ジスルフィド異性化酵素およびａｂｃ輸送体の相同性タンパク質
JP2005514940A (ja) １４３５分子、５５９分子、３４０２１分子、４４０９９分子、２５２７８分子、６４１分子、２６０分子、５５０８９分子、２１４０７分子、４２０３２分子、４６６５６分子、６２５５３分子、３０２分子、３２３分子、１２３０３分子、９８５分子、１３２３７分子、１３６０１分子、１８９２６分子、３１８分子、２０５８分子または６３５１分子を用いる泌尿器疾患を処置するための方法および組成物
WO2003005034A2 (fr) Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
CA2801162A1 (fr) Applications de diagnostic, de depistage et therapeutiques d'outils a base de la proteine ocab
JP2005511660A6 (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
JP2005511660A (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
US20060153806A1 (en) Proteins involved in the regulation of energy homeostasis
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
CA2424932A1 (fr) Cd36 en tant que recepteur de la proteine de choc thermique et ses utilisations
US20050283842A1 (en) Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
WO2004064856A2 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
JP2005506042A (ja) 細胞トランスポーターをコードするポリヌクレオチド、およびその使用方法
US20080107639A1 (en) Use of a Dg147 Protein Product for Preventing and Treating Metabolic Disorders
JP2006519757A (ja) エネルギー恒常性の調節に関与するタンパク質

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20041005